Adenosine pathway and cancer: Where do we go from here?

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 9, 2014, Pages 973-977

  Antonioli, Luca ^a,b   Haskó, György ^b   Fornai, Matteo ^a   Colucci, Rocchina ^a   Blandizzi, Corrado ^a  

^a UNIVERSITY OF PISA   (Italy)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Adenosine; Adenosine receptors; Cancer; CD73; Immune system; Inflammation; Novel therapies

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE RECEPTOR; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CELL PROLIFERATION; GENE EXPRESSION; HUMAN; IMMUNOLOGICAL TOLERANCE; METASTASIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE COURSE; DRUG DESIGN; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

5'-NUCLEOTIDASE; ADENOSINE; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84906240747     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.925883     Document Type: Review

References (24)

1. Allard B, Turcotte M, Stagg J. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opin Ther Targets 2014;18(8):863-81
2. Antonioli L, Blandizzi C, Pacher P, et al. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013;13(12):842-57
3. Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2009;30(3):102-8
4. Antonioli L, Pacher P, Vizi ES, et al. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013;19(6):355-67
5. Lukashev D, Ohta A, Sitkovsky M. Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev 2007;26(2):273-9
6. Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 2010;70(6):2245-55
7. Waickman AT, Alme A, Senaldi L, et al. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 2012;61(6):917-26
8. Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci USA 2013;110(36):14711-16
9. Synnestvedt K, Furuta GT, Comerford KM, et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002;110(7):993-1002
10. Spychala J, Kitajewski J. Wnt and betacatenin signaling target the expression of ecto-5'-nucleotidase and increase extracellular adenosine generation. Exp Cell Res 2004;296(2):99-108
11. Allard B, Turcotte M, Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012;2012:485156
12. Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011;71(8):2892-900
13. Allard B, Turcotte M, Spring K, et al. Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer 2014;134(6):1466-73
14. Ghiringhelli F, Bruchard M, Chalmin F, et al. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012;2012:473712
15. Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010;107(4):1547-52
16. Rust S, Guillard S, Sachsenmeier K, et al. Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type. Mol Cancer 2013;12:11
17. Loi S, Pommey S, Haibe-Kains B, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA 2013;110(27):11091-6
18. Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res 2010;70(16):6407-11
19. Haskó G, Kuhel DG, Chen JF, et al. Adenosine inhibits IL-12 and TNF- [alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000;14(13):2065-74
20. Haskó G, Szabó C, Németh ZH, et al. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264. 7 macrophages and in endotoxemic mice. J Immunol 1996;157(10):4634-40
21. Nakatsukasa H, Tsukimoto M, Harada H, et al. Adenosine A2B receptor antagonist suppresses differentiation to regulatory T cells without suppressing activation of T cells. Biochem Biophys Res Commun 2011;409(1):114-19
22. Iannone R, Miele L, Maiolino P, et al. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 2013;15(12):1400-9
23. Stemmer SM, Benjaminov O, Medalia G, et al. CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label,dose-escalation study. Oncologist 2013;18(1):25-6
24. Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006;103(35):13132-7